Evaluation of modified risk claim advertising formats for Camel Snus

Health Education Journal

Volumn 76, Issue 8, 2017, Pages 971-985

  Fix, Brian V ^a   Adkison, Sarah E ^a   O’Connor, Richard J ^a   Bansal Travers, Maansi ^a   Cummings, K Michael ^b   Rees, Vaughan W ^c   Hatsukami, Dorothy K ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Advertising; consumer behaviour; modified risk; Snus; tobacco

Indexed keywords

NITROSAMINE;

ADOLESCENT; ADULT; ADVERTISING; AGED; ARTICLE; AWARENESS; CONSUMER ATTITUDE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH BEHAVIOR; HEALTH HAZARD; HEALTH STATUS; HUMAN; MALE; PACKAGING; PRIORITY JOURNAL; RISK REDUCTION; SNUS; TOBACCO USE; YOUNG ADULT;

EID: 85035786185     PISSN: 00178969     EISSN: 17488176     Source Type: Journal    
DOI: 10.1177/0017896917729723     Document Type: Article

References (45)

1. Ancker JS, Senathirajah Y, Kukafka R. (2006) Design features of graphs in health risk communication: A systematic review. Journal of the American Medical Informatics Association 13(6): 608–618.
2. Bansal-Travers M, Hammond D, Smith P. (2011) The impact of cigarette pack design, descriptors, and warning labels on risk perception in the U.S. American Journal of Preventive Medicine 40(6): 674–682.
3. Bansal-Travers M, O’Connor R, Fix BV. (2011) What do cigarette pack colors communicate to smokers in the U.S.? American Journal of Preventive Medicine 40(6): 683–689.
4. Biener L, Bogen K, Connolly G, (2007) Impact of corrective health information on consumers’ perceptions of ‘reduced exposure’ tobacco products. Tobacco Control 16(5): 306–311.
5. Biener L, Mccausland K, Curry L. (2011) Prevalence of trial of Snus products among adult smokers. American Journal of Public Health 101(10): 1874–1876.
6. Biener L, Roman AM, McInerney SA. (2016) Snus use and rejection in the USA. Tobacco Control 25(4): 386–392.
7. Chang JT, Levy DT, Meza R, (2016) Trends and factors related to smokeless tobacco use in the united states. Nicotine & Tobacco Research 18: 1740–1748.
8. Dave DM, Saffer H, (2013) Demand for smokeless tobacco: Role of advertising. Journal of Health Economics 32: 682–697.
9. Delnevo CD, Wackowski OA, Giovenco DP. (2012) Examining market trends in the United States smokeless tobacco use: 2005–2011. Tobacco Control 23(2): 107–112.
10. Ellwood KC, Trumbo PR, Kavanaugh CJ, (2010) How the US food and drug administration evaluates the scientific evidence for health claims. Nutrition Reviews 68(2): 114–121.
11. Gartner CE, Hall WD, Chapman S. (2007) Should the health community promote smokeless tobacco (Snus) as a harm reduction measure? PLoS Medicine 4: e185.
12. Hall MG, Ribisl KM, Brewer NT, (2013) Smokers’ and nonsmokers’ beliefs about harmful tobacco constituents: Implications for FDA communication efforts. Nicotine & Tobacco Research 16(3): 343–350.
13. Hatsukami DK, Lemmonds C, Tomar SL, (2004) Smokeless tobacco use: Harm reduction or induction approach? Preventive Medicine 38(3): 309–317.
14. Hatsukami DK, Stepanov I, Severson H. (2015) Evidence supporting product standards for carcinogens in smokeless tobacco products. Cancer Prevention Research 8(1): 20–26.
15. Hecht SS, (2014) It is time to regulate carcinogenic tobacco-specific nitrosamines in cigarette tobacco. Cancer Prevention Research 7(7): 639–647.
16. Institute of Medicine of the National Academies (2012) Scientific standards for studies on modified risk tobacco products. Available at: https://www.nationalacademies.org/hmd/~/media/Files/Activity%20Files/PublicHealth/Modified-Risk-Tobacco/MRTP_rb.pdf (accessed 7 September 2016).
17. Kapsak WR, Schmidt D, Childs NM. (2008) Consumer perceptions of graded, graphic and text label presentations for qualified health claims. Critical Reviews in Food Science and Nutrition 48(3): 248–256.
18. Kaufman AR, Mays D, Koblitz AR. (2014) Judgments, awareness, and the use of Snus among adults in the United States. Nicotine & Tobacco Research 16(10): 1404–1408.
19. Kiviniemi MT, Kozlowski LT, (2015) Deficiencies in public understanding about tobacco harm reduction: Results from a United States national survey. Harm Reduction Journal 12(1).
20. Kostygina G, England L, Ling P, (2016) New product marketing blurs the line between nicotine replacement therapy and smokeless tobacco products. American Journal of Public Health 106(7): 1219–1222.
21. Kozlowski L, Sweanor D, (2016) Withholding differential risk information on legal consumer nicotine/tobacco products: The public health ethics of health information quarantines. The International Journal on Drug Policy 32: 17–23.
22. Kozlowski LT, Abrams DB, (2016) Obsolete tobacco control themes can be hazardous to public health: The need for updating views on absolute product risks and harm reduction. BMC Public Health 16: 432. Available at: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-016-3079-9
23. Levy DT, Mumford EA, Cummings KM. (2004) The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: Estimates of a panel of experts. Cancer Epidemiology, Biomarkers & Prevention 13: 2035–2042.
24. McCaffery KJ, Dixon A, Hayen A. (2012) The influence of graphic display format on the interpretations of quantitative risk information among adults with lower education and literacy: A randomized experimental study. Medical Decision Making: An International Journal of the Society for Medical Decision Making 32: 532–544.
25. Mays D, Moran MB, Levy DT. (2015) The impact of health warning labels for Swedish Snus advertisements on young adults’ Snus perceptions and behavioral intentions. Nicotine & Tobacco Research 18(5): 1371–1375.
26. Moodie C, Ford A, Mackintosh A. (2015) Are all cigarettes just the same? Female’s perceptions of slim, coloured, aromatized and capsule cigarettes. Health Education Research 30(1): 1–12.
27. O’Connor RJ, Bansal-Travers M, Cummings KM. (2015) Filter presence and tipping paper color influence consumer perceptions of cigarettes. BMC Public Health 15: 1279.
28. O’Connor RJ, Norton KJ, Bansal-Travers M. (2011) US smokers’ reactions to a brief trial of oral nicotine products. Harm Reduction Journal 8: 1477–7517.
29. Peeters S, Gilmore AB, (2013) How online sales and promotion of snus contravenes current European union legislation. Tobacco Control 22(4): 266–273.
30. Peeters S, Gilmore AB, (2013) Transnational tobacco company interests in smokeless tobacco in Europe: Analysis of internal industry documents and contemporary industry materials. PLoS Medicine 10(9): e1001506.
31. Popova L, Ling PM, (2014) Nonsmokers’ responses to new warning labels on smokeless tobacco and electronic cigarettes: An experimental study. BMC Public Health 14: 997.
32. Popova L, Neilands TB, Ling PM, (2014) Testing messages to reduce smokers’ openness to using novel smokeless tobacco products. Tobacco Control 23: 313–321.
33. Public Law 111-31 HR 1256 (2016). Available at: http://www.gpo.gov/fdsys/pkg/PLAW-111publ31/pdf/PLAW-111publ31.pdf (accessed 25 April 2016).
34. Rees VW, Kreslake JM, Cummings KM. (2009) Assessing consumer responses to potential reduced-exposure tobacco products: A review of tobacco industry and independent research methods. Cancer Epidemiology, Biomarkers, & Prevention 18: 3225–3240.
35. RJ Reynolds Tobacco Company (2003) Comments to proposed rulemaking, fire safety standards for cigarettes. RJ Reynolds. Available at: http://tobaccodocuments.org (Bates No. 528767372)
36. Schwartz LM, Woloshin S, (2013) The drug facts box: Improving the communication of prescription drug information. Proceedings of the National Academy of Sciences 110(Suppl. 3): 14069–14074.
37. Smith P, Bansal-Travers M, Oconnor R. (2011) Correcting over 50 years of tobacco industry misinformation. American Journal of Preventive Medicine 40(6): 690–698.
38. Tan CE, Kyriss T, Glantz SA, (2013) Tobacco company efforts to influence the food and drug administration-commissioned institute of medicine report clearing the smoke: An analysis of documents released through litigation. PLoS Medicine 10(5): e1001450.
39. Tomar SL, (2007) Epidemiologic perspectives on smokeless tobacco marketing and population harm. American Journal of Preventive Medicine 33(6): S387–S397.
40. Tomar SL, Fox BJ, Severson HH, (2009) Is smokeless tobacco use an appropriate public health strategy for reducing societal harm from cigarette smoking? International Journal of Environmental Research and Public Health 6(1): 10–24.
41. US Department of Health and Human Services (2012) Preventing Tobacco Use among Youth and Young Adults: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
42. US Department of Health and Human Services (2014) The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
43. US District Court for the District of Columbia (2006) No. 99-CV-02496GK (Final Opinion). Available at: http://www.tobaccocontrollaws.org/files/live/litigation/2425/US_United%20States%20v.%20Philip%20Morris.pdf
44. Wackowski OA, Delnevo CD, (2015) Young adults’ risk perceptions of various tobacco products relative to cigarettes. Health Education & Behavior 43(3): 328–336.
45. Wakefield M, Morley C, Horan JK. (2002) The cigarette pack as image: New evidence from tobacco industry documents. Tobacco Control 11(Suppl. 1): i73–i80.